ocular disorder
SpliceBio to Kick off Phase I/II Trial of Stargardt Disease Gene Therapy in 2025
SpliceBio aims to begin a study testing its protein splicing gene therapy in the first half of 2025, now that the FDA has cleared its IND.
Nippon Shinyaku Scoops Up Exclusive Rights to Atsena's LCA Gene Therapy in US, Japan
In the deal, Nippon Shinyaku can exclusively sell ATSN-101 in the US and develop and sell it in Japan, while Atsena retains rights to other territories.
Ocugen Obtains $30M Credit Facility
The company will use the proceeds to develop its gene therapies for eye disorders and for general corporate expenses.
HuidaGene Therapeutics to Launch Wet AMD CRISPR RNA-Editing Trial in US
The FDA has cleared an investigational new drug application enabling the company to begin a Phase I trial of HG202 in patients with the eye disorder.
Ocuphire Pharma, Opus Genetics Merge in All-Stock Deal
The combined company, which will be called Opus Genetics, will focus on advancing a pipeline of gene therapies for inherited retinal diseases.
Jul 24, 2024